Skip to main content

Animations

We are charting the path to a future free from Parkinson’s. Your support will get us there.

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To

Filter Results (222${count})

  • Therapeutics Development Initiative, 2012
    Lead Optimization for a Parkinson's Disease Therapeutic

    Objective/Rationale: 
    CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve…

  • ASAP CRN Discovery Fellowship 2025, 2026
    Does Pathogenic α-Synuclein Disrupt Lipid Droplet–Mitochondria Coupling in Parkinson’s Disease?
    ASAP logo
  • Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026
    ADAPT-GAIT: Adaptive deep brain stimulation controlled by neural biomarkers of gait to alleviate locomotor deficits in people with advanced Parkinson's disease

    Study Rationale:       

    People with advanced Parkinson’s disease often develop severe gait and balance impairments—including asymmetries, instability, and freezing of gait—that are heterogeneous…

  • Resource: Utilizing DATATOP Biospecimens, 2011
    Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease

    Objective/Rationale:
    We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus…

  • Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009
    Utility of the Amyloid Ligand [18F]FDDNP in Human PET Imaging in Parkinson Disease

    Objective/Rationale:
    Biomarkers of Parkinson disease are sorely needed for the assessment of disease status so that they may be used to design more efficient and informative clinical trials of disease…

  • Rapid Response Innovation Awards, 2007
    Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

    Objective/Rationale:
    The objective of this study is to explore the effects of methylphenidate on the gait of patients with Parkinson’s disease who are experiencing shuffling and freezing…

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.